|Dr. Steven J. Mento||Co-Founder, CEO, Pres & Director||835.33k||N/A||1952|
|Dr. Alfred P. Spada Ph.D.||Co-Founder, Chief Scientific Officer and Exec. VP of R&D||589.49k||N/A||1958|
|Dr. David T. Hagerty M.D.||Exec. VP of Clinical Devel.||590.29k||N/A||1955|
|Dr. Keith W. Marshall MBA, Ph.D.||Exec. VP, COO & CFO||N/A||N/A||N/A|
|Ms. Michelle L. Vandertie||Principal Accounting Officer & VP of Fin.||N/A||N/A||1964|
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
Conatus Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 9.